Section 3.1
Skeletal Muscle Relaxants
Distinguish painful muscle spasm from spasticity, explain central versus direct muscle relaxation, and use the mechanism to identify a safety concern.
Learn
Idea 1 / 4
Start with the type of stiffness
A muscle spasm is an involuntary contraction; after a strain, pain and protective muscle tightening can reinforce one another. Spasticity is different: damage to pathways from the brain reduces normal control of spinal stretch reflexes. The muscle resists more when it is stretched faster. This can occur after stroke or in multiple sclerosis. Distinguishing these problems matters because medicines used for a short-lived painful strain are not automatically suitable for long-term spasticity.
A painful back contraction after lifting differs from a leg that repeatedly resists rapid movement months after a stroke. The second pattern suggests a problem with reflex control, not simply a recent muscle strain.
Read all essential notes
Start with the type of stiffness
A muscle spasm is an involuntary contraction; after a strain, pain and protective muscle tightening can reinforce one another. Spasticity is different: damage to pathways from the brain reduces normal control of spinal stretch reflexes. The muscle resists more when it is stretched faster. This can occur after stroke or in multiple sclerosis. Distinguishing these problems matters because medicines used for a short-lived painful strain are not automatically suitable for long-term spasticity.
A painful back contraction after lifting differs from a leg that repeatedly resists rapid movement months after a stroke. The second pattern suggests a problem with reflex control, not simply a recent muscle strain.
Central action changes nerve messages
“Central” means acting in the brain or spinal cord rather than directly on muscle fibers. Cyclobenzaprine and methocarbamol are examples used in selected painful muscle conditions; their precise mechanisms are not completely established. Baclofen is an antispastic medicine: it activates GABA-B receptors, molecular switches responding to an inhibitory messenger called gamma-aminobutyric acid. Tizanidine activates alpha-2 receptors that reduce release of excitatory nerve messengers. These actions can reduce excessive muscle tone, but sleepiness and weakness can limit useful movement.
A stiff leg may become easier to bend, yet standing can become harder if weakness increases. Assess both the reduction in stiffness and the ability to perform useful activities.
Direct action changes calcium inside muscle
A muscle fiber stores calcium inside a compartment called the sarcoplasmic reticulum. When calcium is released, it enables the muscle proteins actin and myosin to interact and generate contraction. Dantrolene reduces this calcium release, acting inside skeletal muscle rather than by blocking the nerve-to-muscle junction. Less contraction can reduce spasticity, but it can also cause weakness. Oral dantrolene carries an important liver-injury warning. Intravenous dantrolene is used by emergency teams for malignant hyperthermia, a dangerous anesthesia-triggered excess of muscle activity and heat production.
Reducing calcium release can weaken a contraction even when a nerve message still reaches the muscle. This differs from reducing the message in the spinal cord.
Judge useful function, not relaxation alone
A medicine is not successful simply because the muscle feels less tight. Compare the person’s comfort, movement, strength and alertness before and after treatment. Other sedating medicines or alcohol can add to central effects. Someone who becomes drowsy should avoid driving or hazardous activity and seek advice about their medicines. New or excessive weakness also needs review. For oral dantrolene, the clinical team additionally considers liver health and monitoring. These are different safety questions arising from different sites of action.
Less stiffness with repeated falls is not an uncomplicated improvement. The fall risk must be considered alongside symptom relief.
Common misconception: All muscle relaxants cause the same paralysis. Central relaxants reduce neural drive, dantrolene changes calcium handling in muscle, and neuromuscular blockers act at a different junction.
Explore
Where does the medicine act?
A schematic teaching plate: follow the message or calcium pathway, then check useful function.
1 / 4 · Excessive reflex drive · Schematic, not to scale; movement is an attention cue, not a validated simulation.
Go deeper: worked example
A learner observes that a patient with longstanding post-stroke leg stiffness can bend the knee more easily after starting an antispastic medicine, but now feels sleepy and needs more help standing. Has the treatment simply succeeded? Work through the information before deciding.
- First identify the original problem. Persistent stiffness following a brain injury fits altered control of stretch reflexes. It is not the same as a brief painful contraction after lifting a heavy object.
- Next separate the observations. Easier bending suggests less excessive tone. Sleepiness suggests a central effect. Needing more assistance to stand suggests that useful function may have worsened despite the reduction in stiffness.
- Connect these observations to the mechanism. Reducing excitatory drive can ease stiffness, but broad effects on the nervous system can reduce alertness or strength. A benefit and an adverse effect can therefore appear together.
- Finally identify the next assessment: review alertness, falls, strength, other sedating substances and the intended functional goal with the clinical team. Do not infer a dose change from this classroom case.
The result is mixed. Symptom relief matters, but safe, useful function is the outcome to assess. Explain both findings rather than treating a looser muscle as the only measure of success.
Explain it yourself
Why can relief and impairment occur together?
Reveal explanation
Central medicines can affect nerve activity involved in both excessive tone and normal alertness or movement. Dantrolene instead reduces calcium-dependent muscle contraction, which may reduce both unwanted stiffness and useful strength. Not every adverse effect shares the therapeutic mechanism: liver injury is a separate safety concern.
Create and evaluate
Create a comparison map for cyclobenzaprine, baclofen, and dantrolene.
Formative activity: compare your reasoning with the rubric. This response is not automatically graded and does not award mastery. It remains only on this page and is cleared when you leave.
Compare with the rubric and example
- Accuracy: name the correct site of action for each medicine; revise any map that puts all three at the nerve-to-muscle junction.
- Causal reasoning: connect each site to reduced tone or contraction, then explain one appropriate safety concern.
- Evaluation: include one functional observation that would challenge an apparent benefit, and explain why it matters.
Cyclobenzaprine: central action may ease a painful spasm but can cause drowsiness. Baclofen: spinal GABA-B activation can reduce excessive reflex activity, with weakness or sedation as possible limits. Dantrolene: reduced calcium release inside muscle reduces contraction, with weakness and a separate liver-risk concern for oral therapy. Easier bending with new falls would challenge the claim that treatment has improved useful function.
Sources and review status
Educational draft. Medical and French-language expert review pending. External sources require an internet connection; essential explanations are included above.
- Clinical Pharmacology Made Incredibly Easy!, 3rd ed. (2009)
Chapter 3: muscle relaxants, printed pp. 49–56; PDF pp. 61–68 (1-based).
- DailyMed: baclofen tablets
Precautions: sedation, driving, additive central effects; accessed 2026-09-21.
- DailyMed: dantrolene sodium capsules
Clinical pharmacology and boxed warning: muscle calcium release, weakness and hepatotoxicity; accessed 2026-09-21.
Check my understanding
Mastery Question Gate
Answer all questions correctly to unlock the next lesson. Retakes vary the selection when enough questions are available; some questions may repeat.
1. What is the primary mechanism of dantrolene in treating malignant hyperthermia?